Neutropenia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022

Description

List of Tables

Neutropenia treatment accounted for a market value of US$ 12,971.08 Mn in 2021 and projected to grow at a CAGR of 5.0% during the forecast period from 2022 to 2030. In neutropenia count of neutrophil falls giving rise to compromised immunity further increasing the risk of infection. Neutropenia is observed in almost half cases of cancer patients being treated with chemotherapy but out of them most are suffering from leukaemia. According to medical experts, neutropenia can be a chronic condition because without adequate neutrophils patient become vulnerable to life-threatening infections.

Strong drug pipeline will assist the significant growth of neutropenia treatment market throughout the forecast period

Drug pipeline of neutropenia treatment is equipped with several promising drugs in phase III of clinical trials such as SPI-2012 (Spectrum Pharmaceuticals, Inc.), F-627 (Generon (Shanghai) Corporation Ltd.), Leucostim (Dong-A ST Co., Ltd.), myelo001 (Myelo Therapeutics, Inc.), Plinabulin (BeyondSpring Pharmaceuticals Inc.), and Romyelocel-L (Cellerant Therapeutics, Inc.). Neutropenia caused due to several causes major being the post-chemotherapy decrease in count of neutrophils. Increasing prevalence of leukemia expected to rise the neutropenia cases as chemotherapy being the first-line of treatment for leukemia. However, precautionary treatment regimen is ready to avoid effect of neutropenia-based infections with antibacterial, antiviral and antifungal drugs.

North America dominated the overall global market specifically due to promising drug pipeline, and developed diagnostic landscape

In 2021, North America dominated the market and expected to retain its position throughout the forecast period due to rising awareness related to neutropenia, increasing prevalence of side effects related to chemotherapy during leukemia treatment, and high expectation from drugs in pipeline. According to several studies, the prevalence of neutropenia is around 4.4% and expected to increase in specific regions with rising prevalence of leukemia. During the forecast period from 2019 to 2027, Asia Pacific will grow gradually due to increasing awareness related to neutropenia diagnosis & treatment coupled with developing diagnostic technologies in rare disease sector.

The key companies included in the neutropenia treatment industry analyzed based on financial data, product portfolio, current press releases, and major market strategies. This report also includes attractive investment proposition studied based on exclusive geographical PESTEL analysis. Major companies included in the report are Amgen, Inc., Spectrum Pharmaceuticals, Inc., Generon (Shanghai) Corporation Ltd., Dong-A ST Co., Ltd., BeyondSpring Pharmaceuticals Inc., Myelo Therapeutics, Inc., Cellerant Therapeutics, Inc., and Sandoz (Subsidiary of Novartis AG) among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Neutropenia Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Neutropenia Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Granulocyte-colony stimulating factor (G-CSF)
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Antibiotics
Antifungal
Antiviral

Region Segment (2020-2030; US$ Million)

North America
- U.S.
- Canada
- Rest of North America

UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe

Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific

Latin America
- Brazil
- Mexico
- Rest of Latin America

Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation
Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Neutropenia Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Neutropenia Treatment market?

Which is the largest regional market for Neutropenia Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Neutropenia Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Neutropenia Treatment market worldwide?

Product Code: 138861-08-22

1. Preface

1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global Neutropenia Treatment Market
2.2. Global Neutropenia Treatment Market, By Drug Class, 2021 (US$ Million)
2.3. Global Neutropenia Treatment Market, By Geography, 2021 (US$ Million)
2.4. Impact of Covid 19
2.5. Attractive Investment Proposition by Geography, 2021
2.6. Competitive Analysis
- 2.6.1. Market Positioning of Key Neutropenia Treatment Market Vendors
- 2.6.2. Strategies Adopted by Neutropenia Treatment Market Vendors
- 2.6.3. Key Industry Strategies

3. Neutropenia Treatment Market: Business Outlook & Market Dynamics

3.1. Introduction
3.2. Global Neutropenia Treatment Market Value, 2020 - 2030, (US$ Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers
- 3.3.2. Market Restraints
- 3.3.3. Key Challenges
- 3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter's Five Force Model
- 3.6.1. Supplier Power
- 3.6.2. Buyer Power
- 3.6.3. Threat Of Substitutes
- 3.6.4. Threat Of New Entrants
- 3.6.5. Competitive Rivalry
3.7. PESTEL Analysis
- 3.7.1. Political Landscape
- 3.7.2. Economic Landscape
- 3.7.3. Technology Landscape
- 3.7.4. Legal Landscape
- 3.7.5. Social Landscape

4. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)

4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
- 4.3.1. Granulocyte-colony stimulating factor (G-CSF)
- 4.3.2. Granulocyte-macrophage colony-stimulating factor (GM-CSF)
- 4.3.3. Antibiotics
- 4.3.4. Antifungal
- 4.3.5. Antiviral

5. North America Neutropenia Treatment Market, 2020-2030, USD (Million)

5.1. Market Overview
5.2. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)
5.3.Neutropenia Treatment Market: By Region, 2020-2030, USD (Million)
- 5.3.1.North America
  - 5.3.1.1. U.S.
  - 5.3.1.2. Canada
  - 5.3.1.3. Rest of North America

6. UK and European Union Neutropenia Treatment Market, 2020-2030, USD (Million)

6.1. Market Overview
6.2. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3.Neutropenia Treatment Market: By Region, 2020-2030, USD (Million)
- 6.3.1.UK and European Union
  - 6.3.1.1. UK
  - 6.3.1.2. Germany
  - 6.3.1.3. Spain
  - 6.3.1.4. Italy
  - 6.3.1.5. France
  - 6.3.1.6. Rest of Europe

7. Asia Pacific Neutropenia Treatment Market, 2020-2030, USD (Million)

7.1. Market Overview
7.2. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.Neutropenia Treatment Market: By Region, 2020-2030, USD (Million)
- 7.3.1.Asia Pacific
  - 7.3.1.1. China
  - 7.3.1.2. Japan
  - 7.3.1.3. India
  - 7.3.1.4. Australia
  - 7.3.1.5. South Korea
  - 7.3.1.6. Rest of Asia Pacific

8. Latin America Neutropenia Treatment Market, 2020-2030, USD (Million)

8.1. Market Overview
8.2. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3.Neutropenia Treatment Market: By Region, 2020-2030, USD (Million)
- 8.3.1.Latin America
  - 8.3.1.1. Brazil
  - 8.3.1.2. Mexico
  - 8.3.1.3. Rest of Latin America

9. Middle East and Africa Neutropenia Treatment Market, 2020-2030, USD (Million)

9.1. Market Overview
9.2. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)
9.3.Neutropenia Treatment Market: By Region, 2020-2030, USD (Million)
- 9.3.1.Middle East and Africa
  - 9.3.1.1. GCC
  - 9.3.1.2. Africa
  - 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

10.1. Amgen, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Portfolio
- 10.1.4. Strategic Initiatives
10.2. Pfizer, Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Portfolio
- 10.2.4. Strategic Initiatives
10.3. Myelo Therapeutics, Inc.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Portfolio
- 10.3.4. Strategic Initiatives
10.4. Cellerant Therapeutics, Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Portfolio
- 10.4.4. Strategic Initiatives
10.5. Sandoz (Subsidary of Novartis AG)
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Portfolio
- 10.5.4. Strategic Initiatives
10.6. BeyondSpring Pharmaceuticals Inc.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Portfolio
- 10.6.4. Strategic Initiatives
10.7. Enzychem Lifesciences Corporation
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Portfolio
- 10.7.4. Strategic Initiatives
10.8. Spectrum Pharmaceuticals, Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Portfolio
- 10.8.4. Strategic Initiatives
10.9. Tianjin SinoBiotech Ltd.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Portfolio
- 10.9.4. Strategic Initiatives
10.10. S&D Pharma SK s.r.o.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Portfolio
- 10.10.4. Strategic Initiatives
10.11. Samsung Medical Center
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Portfolio
- 10.11.4. Strategic Initiatives
10.12. Generon (Shanghai) Corporation Ltd.
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Portfolio
- 10.12.4. Strategic Initiatives
10.13. PhytoHealth Corporation
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Portfolio
- 10.13.4. Strategic Initiatives
10.14. Dong-A ST Co., Ltd.
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Portfolio
- 10.14.4. Strategic Initiatives

Product Code: 138861-08-22

List of Tables

TABLE 1 Global Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)
TABLE 2 North America Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)
TABLE 3 UK and European Union Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)
TABLE 4 Asia Pacific Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)
TABLE 5 Latin America Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)
TABLE 6 Middle East and Africa Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)

List of Figures

FIG. 1 Global Neutropenia Treatment Market: Market Coverage
FIG. 2 Research Methodology and Data Sources
FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
FIG. 4 Global Neutropenia Treatment Market: Quality Assurance
FIG. 5 Global Neutropenia Treatment Market, By Drug Class, 2021
FIG. 6 Global Neutropenia Treatment Market, By Geography, 2021
FIG. 7 Global Neutropenia Treatment Market, By Drug Class, 2021 Vs 2030, %
FIG. 8 U.S. Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 9 Canada Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 10 Rest of North America Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 11 UK Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 12 Germany Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 13 Spain Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 14 Italy Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 15 France Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 16 Rest of Europe Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 17 China Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 18 Japan Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 19 India Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 20 Australia Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 21 South Korea Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 22 Rest of Asia Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 23 Brazil Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 24 Mexico Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 25 Rest of Latin America Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 26 GCC Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 27 Africa Neutropenia Treatment Market (US$ Million), 2020 - 2030
FIG. 28 Rest of Middle East and Africa Neutropenia Treatment Market (US$ Million), 2020 - 2030

Neutropenia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

Description

Table of Contents

List of Tables

Strong drug pipeline will assist the significant growth of neutropenia treatment market throughout the forecast period

North America dominated the overall global market specifically due to promising drug pipeline, and developed diagnostic landscape

Historical & Forecast Period

Research Methodology

Geographical revenues generate by countries considered in the report:

Market Segmentation

Drug Class

Region Segment (2020-2030; US$ Million)

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Key questions answered in this report:

Table of Contents

1. Preface

2. Executive Summary

3. Neutropenia Treatment Market: Business Outlook & Market Dynamics

4. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)

5. North America Neutropenia Treatment Market, 2020-2030, USD (Million)

6. UK and European Union Neutropenia Treatment Market, 2020-2030, USD (Million)

7. Asia Pacific Neutropenia Treatment Market, 2020-2030, USD (Million)

8. Latin America Neutropenia Treatment Market, 2020-2030, USD (Million)

9. Middle East and Africa Neutropenia Treatment Market, 2020-2030, USD (Million)

10. Company Profile

List of Tables

List of Figures